The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
Under the deal, Quiver will receive an undisclosed advance payment and research support
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
Uppilliappan joined Dr. Lal Pathlabs in 2016 as Chief Operating Officer and later became CEO
Subscribe To Our Newsletter & Stay Updated
